Stem Cell Therapy for Systemic Sclerosis Package in Cali, Colombia by Stem Cells Kyron

• Location: Cali, Colombia

• Starting Price: USD 11,000

• Suggested Length of Stay: 4 Days

• Product / Dose / Route: Defined solely after individual medical evaluation

• Status: Investigational intervention; requires comprehensive cardiopulmonary and renal evaluation

Key Information

• Starting Price: USD 11,000. This is a planning estimate and not a final quote until medical review is completed.

• Individual Evaluation: Limited or diffuse subtype, duration, mRSS, Raynaud's and digital ulcers, FVC/DLCO, HRCT, echocardiogram, NT-proBNP, risk of pulmonary hypertension, heart, blood pressure, kidney, and digestive system are reviewed.

• Written Protocol: Prior to acceptance, the patient must receive product identity and source, viable dose, route, volume, infusion rate, quality controls, residual cryoprotectant, timeline regarding immunosuppressants, monitoring, and complication management.

• Continuity of Care: Rheumatology and cardiopulmonary, renal, and gastrointestinal follow-up must be maintained. Immunosuppressants, antifibrotics, vasodilators, or pulmonary hypertension treatment should not be discontinued without indication.

• Realistic Expectations: No guarantee can be made regarding reduction of skin fibrosis, improvement of FVC/DLCO, ulcer healing, prevention of pulmonary hypertension or renal crisis, functional recovery, or medication discontinuation.

• Review of SSc criteria, subtype, mRSS, Raynaud's and ulcers, lungs, pulmonary hypertension, heart, kidneys, digestive tract, treatments, and infections.

• In-person medical consultation and confirmation of eligibility.

• Specific exams defined by protocol.

• Explanation of cellular product: source, processing, identity, dose, route, and quality controls.

• Administration of the product and clinical monitoring.

• Discharge record, post-care instructions, and contact channel.

• Medical summary to share with treating team in country/city of origin.

• Remote follow-up during agreed period.

1. Flights, passports, visas, transfers, lodging, meals, and caregiver expenses.

2. Travel insurance, medical evacuation, or subsequent care outside Kyron.

3. Unplanned tests, specialist consultations, or extended stay.

4. Emergencies, unplanned hospitalization, or treatment of complications.

5. Rheumatology, neurology, gastroenterology, nephrology, pulmonology, dermatology, rehabilitation, or other ongoing care.

6. Repeat procedures or protocol changes not included in the quote.

• SSc confirmed by rheumatology, with subtype, duration, progression, and organ involvement clearly documented.

• Ability to give informed consent and comply with monitoring, standard treatment, and follow-up.

• Insufficient response, intolerance, or progression despite appropriate management for specific manifestation, evaluated at an expert center when high-risk disease exists.

• Realistic goals and explicit acceptance that there is no guarantee of reduced fibrosis, lung recovery, digital ulcer healing, or renal crisis prevention.

• Plan to continue rheumatology, pulmonology, or cardiology care as appropriate, alongside immunosuppression, antifibrotics, vasodilators, rehabilitation, and vascular care.

• Fever, active infection, infected digital ulcer, unevaluated tuberculosis or hepatitis, bacteremia, or sepsis.

• Scleroderma renal crisis, decompensated pulmonary hypertension, severe myocarditis/arrhythmia, rapidly progressive ILD, or critical digital ischemia (requires urgent care).

• Active or suspected cancer, severe pulmonary hypertension, cardiomyopathy, significant arrhythmia, advanced ILD, or decompensated renal failure.

• Uncontrolled blood pressure, severe cytopenias, uncontrolled coagulopathy or thrombotic risk, pregnancy, lactation, or protocol allergies.

• Inability to complete cardiopulmonary/renal evaluation, profound immunosuppression, or lack of coordination with ILD, PAH, or vasculopathy treatments.

• Expectation of curing autoimmunity, stopping standard treatment, or treating multiple diagnoses with a single infusion without specific targets.

• Subtype and duration history, serial mRSS, Raynaud's, ulcers, dyspnea, syncope, reflux/dysphagia, blood pressure, renal function, treatments, infections, and hospitalizations.

• Complete list of corticosteroids, antimalarials, immunosuppressants, biologics, JAK inhibitors, immunoglobulin, anticoagulants, supplements, allergies, and last dose dates.

• Relevant history of infections, oncology, thrombosis, cardiovascular, renal, pulmonary, neurological, gastrointestinal, and obstetric conditions.

• CBC, renal and liver function, urinalysis, CK, autoantibodies; FVC/DLCO, HRCT, ECG, echocardiogram, and NT-proBNP; right heart catheterization when indicated.

• Screening for tuberculosis, hepatitis B and C, and HIV; vaccination and pulmonology/cardiology evaluation based on involvement.

• ID document, emergency contacts, and legal representative documentation when applicable.

1. Consultation with primary physician or independent professional prior to booking.

2. Transmission and review of records by the Kyron team.

3. Clinical pre-selection and request for additional information if required.

4. In-person consultation, physical exam, and plan confirmation.

5. Delivery of protocol, budget, and informed consent.

6. Sufficient time for questions and voluntary decision-making.

7. Administration, observation, and discharge according to approved protocol.

8. Structured follow-up and communication with home healthcare team.

Travel Recommendations

• Travel with a companion when functional limitations, severe fatigue, neurological commitment, thrombotic risk, or significant immunosuppression are present.

• Keep medications in original containers and carry an updated list.

• Use change-friendly tickets when possible.

• Confirm emergency plans during stay and after return.

• Consult regarding thrombotic prevention, vaccines, infection prophylaxis, isolation measures, hydration, and flight fitness.

Recovery and Post-Care First 24–48 Hours

Follow observation and medication instructions. Seek urgent evaluation for fever, shortness of breath, chest pain, bleeding, decreased urination, rapid edema, neurological deficit, unilateral leg swelling, allergic reaction, or major deterioration.

First Week

Log temperature, infection symptoms, rash, pain, dyspnea, edema, diuresis, and disease-specific symptoms. Maintain written treatment plan and do not automatically attribute every change to the infusion.

After Return

Share summary with rheumatology, cardiopulmonary, and renal teams. Response should be measured via mRSS, FVC/DLCO, digital ulcers, cardiac function, blood pressure, kidney metrics, HAQ-DI, and adverse events.

• Pain, bruising, bleeding, phlebitis, or local reaction.

• Fever, headache, nausea, fatigue, or transient inflammatory symptoms.

• Allergic, immunological, or infusion reactions, including hypotension or breathing difficulty.

• Infection, contamination, or pathogen transmission if controls fail.

• Thrombotic, vascular, or respiratory events related to product or delivery.

• Specific risks of administration route, puncture, sedation, or anesthesia.

• Unexpected biological effects, including unwanted cellular proliferation or behavior.

• Lack of benefit, clinical worsening, financial loss, or delayed effective care.

• Infusion reaction, fever, chills, rash, bronchospasm, hypotension, or anaphylaxis.

• Thrombotic events, pulmonary embolism, volume overload, or cardiopulmonary decompensation.

• Effects of residual DMSO or excipients (odor, taste, nausea, headache, hypotension, hypersensitivity).

• Opportunistic infection, digital ulcer infection, or reactivation of TB/hepatitis in immunosuppressed patients.

• Progression of ILD, pulmonary hypertension, fibrosis, digital ischemia, or renal damage due to lack of response or delayed effective therapy.

• No guarantee of skin improvement, Raynaud's, digital ulcers, lung status, pulmonary hypertension, heart, kidney, digestive issues, mobility, quality of life, or medication reduction.

• Changes may coincide with mycophenolate, cyclophosphamide, rituximab, tocilizumab, nintedanib, vasodilators, rehabilitation, natural fluctuation, or contextual placebo effects.

• Unchanged results and adverse events must also be logged.

• Organ-specific management remains essential. MSC infusion must not delay treatment for ILD, pulmonary hypertension, renal crisis, digital ischemia, cardiac involvement, or evaluation for hematopoietic stem cell transplant at an expert center.

1. Are MSCs approved as routine treatment for systemic sclerosis?

No. They must not be presented as approved routine treatment or as a replacement for organ-specific care. Their investigational nature, product details, and regulatory framework must be explained before consent.

2. What is included in the starting price?

An individual itemized quote separating evaluation, tests, product, administration, observation, follow-up, and extra charges will be provided.

3. Can it reverse fibrosis or recover lung function?

No. Reductions in mRSS, FVC/DLCO recovery, ulcer healing, or prevention of renal crisis/pulmonary hypertension cannot be promised.

4. What product information should I request?

Source, donor, lab, traceability, identity, viability, sterility, endotoxins, mycoplasma, dose, route, transport, thawing, and release criteria.

5. How long must we stay in Cali?

Stay length is individualized based on diagnosis, activity, immunosuppression, route, post-infusion reaction, testing, and flight readiness.

6. Are current medications or therapies discontinued?

Do not stop steroids, immunosuppressants, biologics, JAK inhibitors, or anticoagulants independently. Any adjustments must be approved by a specialist.

7. What happens if a problem arises after returning home?

A written contact, clinical record, and local care coordination plan must be provided before travel. Warning signs require immediate emergency care, not just remote tracking.

8. Does a registered clinical trial prove it works?

No. Trial registration does not equal regulatory approval, safety, or proven efficacy for an individual.

9. How do I verify the clinic and product?

Request current provider, practitioner, lab, product, quality control, emergency plan, and consent documents.

10. Is an independent second opinion advisable?

Yes. An independent review helps evaluate risks, alternatives, travel, and follow-up care.

• Received written protocol and understand MSCs for SSc are investigational.

• Aware of product source, identity, dose, route, and quality controls.

• Received itemized budget and aware of non-included costs.

• Understand risks, alternatives, uncertainties, and possibility of zero benefit.

• Know responsible physician and how to verify credentials.

• Aware of emergency, hospital referral, and follow-up plans.

• Consulted primary physician or independent professional.

• Have flexible and safe travel plan.

• Will not alter steroids, immunosuppressants, biologics, JAK inhibitors, or anticoagulants without medical direction.

• Keep copies of consent, test results, product certificates, and discharge summary.

• Reported Standard Product: Umbilical cord MSCs; each batch must have identity, post-thaw viability, sterility, endotoxin, mycoplasma, traceability, and certificate of analysis.

• Kyron Protocol Dosing Range: 50–100 million viable IV cells. SSc research uses varied sources, doses, and routes; no automatic equivalence or universal dose exists.

• Administration: Document volume, rate, filter, premedication, residual DMSO, and monitoring. Coordinate vaccines, prophylaxis, and immunosuppressive care; avoid concurrent combinations that obscure safety or efficacy assessment.

Take the Vital Step Toward Rejuvenation

If systemic sclerosis is affecting your comfort, mobility, or daily quality of life, exploring your treatment options can be an important next step. PlacidWay Medical Tourism can help you learn more about the Stem Cell Therapy for Systemic Sclerosis Package at Stem Cells Kyron in Cali, Colombia, connect with the provider, and request information about the treatment process, eligibility, and clinical considerations.

• International Society for Stem Cell Research (ISSCR): Patient Handbook on Stem Cell Therapies.

• U.S. Food and Drug Administration (FDA): Consumer Information on Regenerative Medicine Products.

• EULAR: Recommendations for SSc management by manifestation; EBMT: Selection and risks of autologous hematopoietic stem cell transplantation.

• PubMed & ClinicalTrials.gov: MSC studies and cellular therapies in SSc.

• European Society for Blood and Marrow Transplantation (EBMT): Guidelines on hematopoietic transplants in severe autoimmune diseases.

• Applicable Colombian regulations (Ministry of Health, INVIMA, regional authorities) — mandatory legal review required prior to publication.